In Canada, switching to a one-dose, gender-neutral vaccination program for human papillomavirus (HPV) could use vaccine doses more efficiently and prevent a similar number of cervical cancer cases, ...

Throughout the past decade, Northwestern University scientists have uncovered a striking principle of vaccine design: Performance depends not only on vaccine components but also on vaccine structure.

The vaccine against human papillomavirus, or HPV, has reduced cervical cancer by nearly 90% in women vaccinated as ...

CEPI has approved the advancement of the vaccine program following promising proof-of-concept results generated by Vaxxas in preclinical models, showing excellent thermostability and effective ...

Screening for cervical cancer every 15 to 25 years was cost-effective for women vaccinated against HPV between the ages of 12 and 24 years.

COVID-19 vaccination mandates and requirements can be effective in increasing vaccination rates, but their success depends on being targeted and on building trust, says a new rapid expert consultation ...

Evaxion A/S has announced the initiation of a new vaccine program, EVX-B4, targeting Group A Streptococcus (GAS), a pathogen responsible for a wide range of infections globally, including severe ...